Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2018
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2018
SUMMARY
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohn's disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1.
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5, 3 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Central Nervous System, Immunology, Infectious Disease, Oncology, Respiratory, Cardiovascular, Genetic Disorders, Ophthalmology and Toxicology which include indications Ulcerative Colitis, Asthma, Crohn's Disease (Regional Enteritis), Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammatory Bowel Disease, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Macular Degeneration, Autoimmune Disorders, Celiac Disease, Chemotherapy Effects, Duchenne Muscular Dystrophy, Epilepsy, Genital Warts (Condylomata Acuminata), Melanoma, Multiple Sclerosis, Paraneoplastic Syndrome and Relapsing Remitting Multiple Sclerosis (RRMS).
The latest report Integrin Alpha 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohn's disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1.
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5, 3 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Central Nervous System, Immunology, Infectious Disease, Oncology, Respiratory, Cardiovascular, Genetic Disorders, Ophthalmology and Toxicology which include indications Ulcerative Colitis, Asthma, Crohn's Disease (Regional Enteritis), Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammatory Bowel Disease, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Macular Degeneration, Autoimmune Disorders, Celiac Disease, Chemotherapy Effects, Duchenne Muscular Dystrophy, Epilepsy, Genital Warts (Condylomata Acuminata), Melanoma, Multiple Sclerosis, Paraneoplastic Syndrome and Relapsing Remitting Multiple Sclerosis (RRMS).
The latest report Integrin Alpha 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
- The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development
Amgen Inc
Antisense Therapeutics Ltd
Biogen Inc
BioMAS Ltd
Daiichi Sankyo Co Ltd
EA Pharma Co Ltd
Immunwork Inc
Morphic Therapeutic Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Viriom Inc
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles
abrilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATL-1102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carotegrast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ET-3764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
natalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTG-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TE-5232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-4500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones
Featured News & Press Releases
Jan 04, 2018: Protagonist Therapeutics Granted New US Patent for Peptide Drug Candidate PTG-100
Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts
Nov 21, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Status Update
Nov 09, 2017: New Post-Hoc Analysis Evaluating Deep Remission with Entyvio (vedolizumab) in Patients with Moderately to Severely Active Ulcerative Colitis Recognized as 'Poster of Distinction' at AIBD 2017 Annual Conferenc
Nov 01, 2017: Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
Oct 30, 2017: ATL1102 'Black Hole' MS data presented at the 7th Joint ECTRIMS-ACTRIMS Meeting
Oct 17, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update
Oct 16, 2017: New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio (vedolizumab), Particularly in Biologic-Na?ve Patients
Oct 02, 2017: Antisense Therapeutics Provides Update on Multiple Sclerosis Drug Candidate ATL1102
Sep 12, 2017: Antisense Therapeutics Announces Update on ATL1102
Aug 22, 2017: Takeda Submits a New Drug Application for Vedolizumab for the Treatment of Moderately to Severely Ulcerative Colitis in Japan
Jul 27, 2017: Antisense Therapeutics Provides Phase IIb Trial Update on ATL1102 for Multiple Sclerosis
Jun 26, 2017: Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy
Jun 26, 2017: ATL1102 for Multiple Sclerosis-Phase IIb Investigational New Drug Application Submitted to the FDA
Jun 16, 2017: Positive effects seen with ATL1102 on Multiple Sclerosis “Black Hole” brain lesions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development
Amgen Inc
Antisense Therapeutics Ltd
Biogen Inc
BioMAS Ltd
Daiichi Sankyo Co Ltd
EA Pharma Co Ltd
Immunwork Inc
Morphic Therapeutic Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Viriom Inc
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles
abrilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATL-1102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carotegrast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ET-3764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
natalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTG-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TE-5232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-4500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones
Featured News & Press Releases
Jan 04, 2018: Protagonist Therapeutics Granted New US Patent for Peptide Drug Candidate PTG-100
Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts
Nov 21, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Status Update
Nov 09, 2017: New Post-Hoc Analysis Evaluating Deep Remission with Entyvio (vedolizumab) in Patients with Moderately to Severely Active Ulcerative Colitis Recognized as 'Poster of Distinction' at AIBD 2017 Annual Conferenc
Nov 01, 2017: Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn’s Disease
Oct 30, 2017: ATL1102 'Black Hole' MS data presented at the 7th Joint ECTRIMS-ACTRIMS Meeting
Oct 17, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update
Oct 16, 2017: New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio (vedolizumab), Particularly in Biologic-Na?ve Patients
Oct 02, 2017: Antisense Therapeutics Provides Update on Multiple Sclerosis Drug Candidate ATL1102
Sep 12, 2017: Antisense Therapeutics Announces Update on ATL1102
Aug 22, 2017: Takeda Submits a New Drug Application for Vedolizumab for the Treatment of Moderately to Severely Ulcerative Colitis in Japan
Jul 27, 2017: Antisense Therapeutics Provides Phase IIb Trial Update on ATL1102 for Multiple Sclerosis
Jun 26, 2017: Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy
Jun 26, 2017: ATL1102 for Multiple Sclerosis-Phase IIb Investigational New Drug Application Submitted to the FDA
Jun 16, 2017: Positive effects seen with ATL1102 on Multiple Sclerosis “Black Hole” brain lesions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by Antisense Therapeutics Ltd, H1 2018
Pipeline by Biogen Inc, H1 2018
Pipeline by BioMAS Ltd, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by EA Pharma Co Ltd, H1 2018
Pipeline by Immunwork Inc, H1 2018
Pipeline by Morphic Therapeutic Inc, H1 2018
Pipeline by Protagonist Therapeutics Inc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Pipeline by Viriom Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Amgen Inc, H1 2018
Pipeline by Antisense Therapeutics Ltd, H1 2018
Pipeline by Biogen Inc, H1 2018
Pipeline by BioMAS Ltd, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by EA Pharma Co Ltd, H1 2018
Pipeline by Immunwork Inc, H1 2018
Pipeline by Morphic Therapeutic Inc, H1 2018
Pipeline by Protagonist Therapeutics Inc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Pipeline by Viriom Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Amgen Inc
Antisense Therapeutics Ltd
Biogen Inc
BioMAS Ltd
Daiichi Sankyo Co Ltd
EA Pharma Co Ltd
Immunwork Inc
Morphic Therapeutic Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Viriom Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Amgen Inc
Antisense Therapeutics Ltd
Biogen Inc
BioMAS Ltd
Daiichi Sankyo Co Ltd
EA Pharma Co Ltd
Immunwork Inc
Morphic Therapeutic Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Viriom Inc
